Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 416-730-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A seven day study (dose-range finder) and a 28d study in rats (EU B.7, OECD 407, GLP) were performed to evaluate the subacute repeated dose toxicity of the test substance. The test substance did not induce any mortalities, abnormalities or clinical symptoms. Based on the results of these studies, the NOEL and the NOAEL of the test substance is 1000 mg/kg bw per day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 12 May 1981
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Lot/batch number of test material: KL384
- Expiration date of the lot/batch: not specified
- Purity test date: not specified
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature in the dark
- Stability under storage conditions: not specified
- Stability under test conditions: The chemical stability and homogeneity of test substance formulations were assessed prior to the start of treatment and concentration analyses of formulations prepared for administration on Days 1 and 22 were performed by the testing facility. The results confirm that specimen formulations were homogeneous and stable for a 4-hour period representing the maximum time from preparation to completion of dosing.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: mixed with the vehicle (1% w/v aqueous methylcellulose)
- Final dilution of a dissolved solid, stock liquid or gel: not specified
FORM AS APPLIED IN THE TEST (if different from that of starting material): mixed with the vehicle. Formulations were prepared freshly each day. - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd., Margate, Kent, England
- Age at study initiation: 28 ± 1 d (on arrival)
- Weight at study initiation: males: 181 g (mean); females: 165.5 g (mean)
- Fasting period before study: no
- Housing: 5 rats of the same sex per cage
- Diet: standard pelleted laboratory rodent diet ad libitum
- Water: drinking water ad libitum
- Acclimation period: 13 days
- Microbiological status when known: not specified
- Method of randomisation in assigning animals to test and control groups: Four days prior to the start of treatment each animal was weighed and sixty rats were randomly allocated to four groups, two groups consisting of ten males and ten females and two groups consisting of five males and five females. This allocation was carried out using a computer program, so that the weight distribution within each group was similar and the initial group mean bodyweights were approximately equalised.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.5 - 25
- Humidity (%): 39 - 71
- Air changes (per hr): approx. 19
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 13 July 1994 (arrival date) To: not specified - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was weighed out and mixed with the vehicle (1% w/v aqueous methylcellulose) using a high shear homogeniser. For each concentration this process was repeated. Formulations were prepared freshly each day. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The chemical stability and, homogeneity of test substance formulations were assessed prior to the start of treatment and, concentration analyses of formulations prepared for administration on Days 1 and 22 were performed by the testing facility.
The analytical results confirm that the doses were accurately formulated for Day 1 and Day 22 of the toxicity study. The results also confirm that specimen formulations were homogeneous and stable for a 4-hour period representing the maximum time from preparation to completion of dosing. - Duration of treatment / exposure:
- 28 d
- Frequency of treatment:
- once daily
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10 for high dose and control
5 for low and mid dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The high dosage was selected on the basis of available toxicity data and a preliminary oral toxicity investigation. A dosage of 1000 mg/kg/day is the limit level for this study design.
- Rationale for selecting satellite groups: not specified
- Post-exposure recovery period in satellite groups: Following the 4 week treatment period, five male and five female animals from Groups 1 and 4 (lowest animal numbers were selected) and surviving animals of Groups 2 and 3 were killed on Day 32 (post-treatment sacrifice). These rats were dosed until the day prior to sacrifice. The remaining animals of Groups 1 and 4 were retained for a 2 week post-treatment observation period and were killed on Day 46 (recovery sacrifice); these rats received their last dose on Day 28.
- Section schedule rationale (if not random): not specified - Positive control:
- none
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: 3 x daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION: Yes
- The quantity of food consumed in each cage was measured at weekly intervals throughout the study
FOOD EFFICIENCY: No
WATER CONSUMPTION: Yes
- Time schedule for examinations: daily
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of treatment period (day 30); for remaining rats after the 2 week recovery period (Day 44)
- Anaesthetic used for blood collection: Yes (light ether anaesthesia)
- Animals fasted: Yes (overnight)
- How many animals: five male and five female rats selected from vehicle control and high dose group and all rats of low and mid dose groups
- Parameters examined: Packed cell volume (PCV), Haemoglobin (Hb), Red blood cell count (RBC), Mean corpuscular haemoglobin concentration (MCHC), Mean corpuscular volume (MCV), Platelet count (Plts), Total white blood cell count (WBC), Thrombotest (TT), Neutrophils (N), Lymphocytes (L), Eosinophils (E), Basophils (B), Monocytes (M)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of treatment period (day 30); for remaining rats after the 2 week recovery period (Day 44)
- Animals fasted: Yes (overnight)
- How many animals: five male and five female rats selected from vehicle control and high dose group and all rats of low and mid dose groups
- Parameters examined: Glucose, Total protein, Albumin (Alb), Globulin (Glob), Albumin/Globulin ratio (A/G), Urea nitrogen (Urea Nitr), Creatinine, Alkaline phosphatase (AP), Glutamic-pyruvic transaminase (GPT), Glutamic-oxaloacetic transaminase (GOT), Gamma-glutamyltransferase (γ-GT), Total bilirubin (Bilirubin), Sodium (Na), Potassium (K), Calcium (Ca), Chloride (Cl), Inorganic phosphorus (P), Cholesterol (Chol), Triglycerides (Tri-glyc)
URINALYSIS: Yes
- Time schedule for collection of urine: at the end of treatment period (day 30); for remaining rats after the 2 week recovery period (Day 44)
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes (overnight)
- Parameters examined: Volume (Vol), pH, protein (not determined for recovery male animals), Total reducing substances (TRS), Glucose, Ketones, Bile pigments, Urobilinogen, Haem pigments
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
adrenals*, aorta, brain (medullary, cerebellar and cortical sections), caecum, colon, duodenum, eyes (Davidson's fluid as fixative), femur (for bone and marrow sections) with joint Harderian gland, heart*, head (to preserve nasal cavity, paranasal, inuses, oral cavity, nasopharynx, middle ear, teeth, lachrymal gland and Zymbal's gland), ileum, jejunum, kidneys, larynx, liver*, lungs, lymph nodes (cervical and mesenteric*), mammary gland, oesophagus, ovaries, pancreas, pharynx, pimitary, prostate, rectum
salivary gland, sciatic nerve, seminal vesicles, skeletal muscle, skin, spinal cord (cervical level), spleen*, stomach, sternum, testes including epididymides* (Bouins as fixative), thymus (where present), thyroid (with parathyroid), tongue, trachea, urinary bladder, uterus (with cervix), vagina, any macroscopically abnormal tissue*
* Tissues required for histopathological examination for rats from vehicle group and high dose group
HISTOPATHOLOGY: Yes - Statistics:
- All statistical analyses were carried out separately for males and females using the individual animal as the basic experimental unit. Different sequence of statistical tests was used for bodyweight gains, food consumption (using weekly cage totals), organ weight and clinical pathology data.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Details on results:
- The only clinical observation during the treatment period of the study was yellow-coloured faeces on the cage tray paper under the cages of rats receiving 1000 mg/kg/day. This incidental finding was considered to be due to the presence of the test substance in the faeces and not a manifestation of toxicity.
After the recovery period, kidney weight (bodyweight adjusted) was statistically significantly lower than the control for male rats treated at 1000 mg/kg/day and higher than control adrenal weights were recorded for female rats treated at 1000 mg/kg/day. In the absence of any treatment-related effects on these organs at Week 5 these small differences from control were considered to reflect variation. - Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: No effects observed up to and including the highest tested dose.
- Critical effects observed:
- no
- Conclusions:
- It was concluded that 1000 mg/kg/day represents the no-observed effect level (NOEL) for the test substance in the rat.
- Executive summary:
The substance was administered by oral gavage, once daily, to three groups of rats for a minimiun of twenty eight consecutive days, at dosage levels of 15, 150 or 1000 mg/kg/day. The test material was prepared as suspensions in 1% w/v aqueous methylcellulose (1% MC) at concentrations of 0.15, 1.5 or 10% w/v and was administered at a dosage volume of 10 ml/kg/day. Control animals received the vehicle (1% MC) alone at the same dose volume (10 ml/kg/day).
All rats of Groups 2 and 3 (15 and 150 mg/kg/day respectively) and five males and five females from each of Groups 1 and 4 (Control and 1000 mg/kg/day respectively) were killed following the fourweek treatment period (Day 32). The remaining animals (five males and five females from Groups 1 and 4) were retained for a two-week recovery period, following which, they were also killed (Day 46).
Bodyweights, food consumption and clinical observations were recorded during the study. Blood and urine samples were taken from all rats shortly prior to termination following the four-week treatment and two-week recovery periods. All animals were killed and subsequently examined macroscopically; specified tissues were then prepared for histopathological examination.
There were no changes seen in the parameters measured in this study namely clinical signs, bodyweights, food consumption, clinical pathology, organ weight analysis, macroscopic or microscopic pathology.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A pre-test and a main study were performed to evaluate the subacute repeated dose toxicity of the test substance in rats. In the pre-study, the test substance was administered orally to a group of three male and three female rats at 1000 mg/kg/day (at a dosage volume of 10 ml/kg/day), formulated as a 10% w/v suspension in 1 % w/v aqueous methylcellulose (1 % MC). A further group of three male and three female rats received the vehicle (1 % MC) alone as a control. The study started on 14 June 1994 and following seven consecutive days of treatment all animals were killed on Day 8 (21 June 1994). Clinical signs, bodyweight, food consumption, organ weight and macroscopic examinations were recorded for the study.
There were no mortalities. No treatment-related clinical signs were noted for any of the animals throughout the study. The only clinical observation during the study was yellow-coloured faeces on the tray paper for all rats receiving 1000 mg/kg/day. No treatment related effects on organ weight, water consumption or food consumption were observed. There were no macroscopic abnormalities observed in any rats.
In the main study, the substance was administered by oral gavage, once daily, to three groups of rats for a minimum for twenty eight consecutive days, at dosage levels of 15, 150 or 1000 mg/kg/day. The test material was prepared as suspensions in 1% w/v aqueous methylcellulose (1% MC) at concentrations of 0.15, 1.5 or 10% w/v and was administered at a dosage volume of 10 ml/kg/day. Control animals received the vehicle (1% MC) alone at the same dose volume (10 ml/kg/day).
All rats of Groups 2 and 3 (15 and 150 mg/kg/day respectively) and five males and five females from each of Groups 1 and 4 (Control and 1000 mg/kg/day respectively) were killed following the fourweek treatment period (Day 32). The remaining animals (five males and five females from Groups 1 and 4) were retained for a two-week recovery period, following which, they were also killed (Day 46).
Bodyweights, food consumption and clinical observations were recorded during the study. Blood and urine samples were taken from all rats shortly prior to termination following the four-week treatment and two-week recovery periods. All animals were killed and subsequently examined macroscopically; specified tissues were then prepared for histopathological examination.
There were no changes seen in the parameters measured in this study namely clinical signs, bodyweights, food consumption, clinical pathology, organ weight analysis, macroscopic or microscopic pathology, that were considered to be related to treatment with the test substance.
The test substance did not induce any mortalities, abnormalities or clinical symptoms. The only remarkable finding in the pre-study was a yellow discoloration of faeces. This incidental finding was considered to be due to the presence of the test substance in the faeces and not a manifestation of toxicity. Based on the results of these studies, the NOEL and the NOAEL of the test substance is 1000 mg/kg bw per day.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. The NOEL and the NOAEL of the test substance was 1000 mg/kg bw per day in an oral subacute repeated dose study. As a result the substance is not considered to be classified for repeated dose toxicity under Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.